UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company with a market capitalization of $483 million and impressive gross profit margins of 90%, recently reported insider transactions by Jason Drew ...
In a recent transaction reported to the SEC, Mark Schoenberg, the Chief Medical (TASE:PMCN) Officer of UroGen Pharma Ltd. (NASDAQ:URGN), sold company shares valued at approximately $50,698. The sales, ...
Pavone discusses how these methods can be used to combat a lack of diversity in clinical trials. While challenges remain, AI is accelerating the process by enabling researchers to identify and design ...
Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, ...
After hours: February 7 at 4:02:42 PM EST Loading Chart for URGN ...
The Decipher Bladder test helps identify aggressive bladder cancer by analyzing tumor molecular subtypes, guiding treatment decisions for neoadjuvant chemotherapy. In a study of 226 patients, luminal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback